Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.25% | -14.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.25% | -14.33% | |||
| Cost of Revenue | -1.97% | -25.73% | |||
| Gross Profit | 1.69% | 27.79% | |||
| SG&A Expenses | 5.95% | 50.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.82% | -9.60% | |||
| Operating Income | -1.35% | 8.95% | |||
| Income Before Tax | -0.07% | 11.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.07% | 11.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.07% | 11.44% | |||
| EBIT | -1.35% | 8.95% | |||
| EBITDA | 0.91% | 9.12% | |||
| EPS Basic | 5.79% | 11.63% | |||
| Normalized Basic EPS | 3.87% | 8.78% | |||
| EPS Diluted | 5.79% | 11.63% | |||
| Normalized Diluted EPS | 3.87% | 8.78% | |||
| Average Basic Shares Outstanding | 6.22% | 0.22% | |||
| Average Diluted Shares Outstanding | 6.22% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||